Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
investorenquiries@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • PharmAust Management
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL Veterinary Trial Details
    • MPL and Veterinary Trials
    • Veterinary Trial Testimonials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
    • Motor Neuron Disease Trial
  • INVESTOR CENTRE
    • PhamAust AGM 2022
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Podcast Episode 18: Dr Kim Agnew, PharmAust
    • Fireside Chat with Dr Roger Aston
    • Fireside Chat with Dr Kim
    • PharmAust Webinar
    • Epichem Webinar
    • BB PAA Video – September 2021
    • OHD Benchtop Flow Reactor Launch
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Author Archives: PharmAust

PharmAust secures patent in US for new portfolio of anticancer drugs

News & Announcements 2017By PharmAustNovember 16, 2017

17113_MPL4_US_New drugs patented for cancer_(clean)

Dogs needed to help evaluate a promising new anti-cancer drug

News & Announcements 2017, Press ReleaseBy PharmAustNovember 13, 2017

New cancer treatment available for dogs with lymphoma

PharmAust subsidiary Epichem named WA exporter of the year

Articles In The NewsBy PharmAustNovember 2, 2017

Epichem Update

News & Announcements 2017By PharmAustNovember 1, 2017

171101_Epichem Update

AGM notice

Financial Reports 2017, News & Announcements 2017By PharmAustNovember 1, 2017

171027_AGM notice

PharmAust achieves key goal with anti-cancer drug

Articles In The NewsBy PharmAustOctober 18, 2017

Monepantel reformulation project continues to progress

News & Announcements 2017By PharmAustOctober 17, 2017

171017_Monepantel reformulation project continues to progress

Corporate Briefing Note

Research Notes 2017By PharmAustOctober 15, 2017

171026-T-PAA-Corporate Briefing Note-AG

PharmAust granted US patent for non-cancer uses of cancer drug

Articles In The NewsBy PharmAustOctober 11, 2017

PharmAust secures broad patent in US for non-cancer applications of Monepantel

News & Announcements 2017By PharmAustOctober 10, 2017

171010_PharmAust secures broad patent in US for non-cancer applications of Monepantel

←1
23456789101112131415161718192021222324252627282930
…3132333435…
363738394041424344454647
48→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER


Facebook
Facebook
fb-share-icon
Twitter
YouTube
TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
28m

MND trial completes enrolment of 'Cohort 2' and prepares for interim analysis
Via @BiotechDispatch
https://biotechdispatch.com.au/news/mnd-trial-completes-enrolment-of-cohort-2-and-prepares-for-inter

Reply on Twitter 1641571161678151680 Retweet on Twitter 1641571161678151680 1 Like on Twitter 1641571161678151680 2 Twitter 1641571161678151680
pharmaust PharmAust @pharmaust ·
16h

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 2 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360
pharmaust PharmAust @pharmaust ·
20h

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 4 Like on Twitter 1641272193236758529 14 Twitter 1641272193236758529
Load More
Copyright © 2023 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top